T3D-959 clinical trials
How each study uses T3D-959 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the T3D-959 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- T3D-959
- 3
Studies by the year they started
3 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2021 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
T3D Therapeutics, Inc. (3)
Studies
Open first, then newest update. How each study uses T3D-959 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease SubjectsNot yet recruitingPhase 2/3T3D Therapeutics, Inc.NCT06964230Written as T3D-959
- Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD SubjectsCompletedPhase 2T3D Therapeutics, Inc.NCT04251182Written as 15mg T3D-959
- Feasibility Study in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedPhase 1/2T3D Therapeutics, Inc.NCT02560753Written as T3D-959
Codes
What other systems call T3D-959 · ClinicalTrials.gg INT018633
- Wikidata Q138042831T3D-959One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q138042831 | T3D-959 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.